Arthur G. Lipman, Pharm.D. - International Association for Hospice ...
Arthur G. Lipman, Pharm.D. - International Association for Hospice ... Arthur G. Lipman, Pharm.D. - International Association for Hospice ...
Arthur G. Lipman Page 24 Extramural Grants and Contracts - continued 1990-1991 Hoechst-Roussell Pharmaceuticals, Inc. Development of a data system for advanced cancer pain and its management, $5,000, Principal investigator. 1994 Syntex Laboratories Development of a continuing education program on pathophysiology and management of pain, $51,425 Principal investigator. 1996-1997 Vista Hospice Care Foundation Postdoctoral training program in pain and palliative care., $58,000 per year, Principal investigator. 1997-1099 VistaCare Foundation, Scottsdale Arizona Support for a Post Doctoral Fellowship in Pain and Palliative Care Pharmacy Research, $66,000 per year, Principal Investigator. 1998-1999 Alza Corporation Evaluation of E-TRANS (iontophoretic delivery) fentanyl for the treatment of breakthrough pain in conjunction with chronic pain, $22,000 Principle Investigator 1998-1999 Durect Corporation Study of subcutaneous sufentanyl in chronic pain management, $56,000, Principle Investigator 1998-1999 Robert Wood Johnson Foundation Utah partnership for improving care at the end of life planning grant, $75,000, Steering Committee member. 1999-2000 Purdue Pharma Physician Perceptions of the Role of Opioids in Chronic Nonmalignant Pain, Principle Investigator, $ 10,000 1999-2001 American Pain Society Development of clinical practice guidelines for pain management in arthritis, Co-Chair-Co Principle Investigator, $25,000 2000-2002 Robert Wood Johnson Foundation Utah partnership for improving care at the end of life implementation grant, $375,000, Steering Committee member 2001 Pharmacia Corp, Systematic Review Of Adverse Effects of Perioperative, Principle Investigator, $10,000 2001 Pharmacia Corp. Costs of adverse reactions to opioids in post surgical patients, Co-Investigator, $125,000 2001 American Pain Society Evidence Based Guidelines Program Systematic Review of the Effect of Pain and Opioids on Immune Response. Principle Investigator, $15,000 2001-2002 Janssen Pharmaceutica Outcomes study of controlled release opioids in low back pain , Co-investigator, 55,000. 2001-2002 Endo Pharamceuticals Dermal Lidocaine for Myofascial Pain, Principle Investigator, $26,000 2002-2007 NIH/NCI 2R01CA07424906A1 Pain and the Defense Response To study the effects of pharmacological manipulated noradrenergic arousal on the defense response. Sub investigator 2003-2004 Progenics Pharmaceuticals MNTX 301 A double-blind placebo-controlled study of methylnaltrexone (MNTX) for the relief of symptomatic constipation due to chronic opioid therapy in patients with advanced medical illness. Principal Investigator 2003-2004 Glaxo Smith Kline SB 767905-001 A randomized, double-blind, placebo-controlled, multicenter phase 3B study to evaluate the efficacy and safety of multiple alvimopan dosage regimens for the treatment of opioid-induced bowel dysfunction in subjects with chronic pain of non-malignant origin. Co-investigator continued
Arthur G. Lipman Page 25 Extramural Grants and Contracts - continued 2004-2005 Progenics Pharmaceuticals MNTX 302 A Double Blind Phase 3, Two-Week, Placebo Controlled Study of Methylnaltrexone (MNTX) for the Relief of Constipation Due to Opioid Therapy in Advanced Medical Illness Principal Investigator 2004-2005 UCB Pharma N02087 A double-blind, randomized, placebo-controlled parallel-group, 16 week, multicenter trial evaluating the efficacy and safety of levetiracetam 500 mg tablets in BID administration (daily dosing range from 1000 mg to 3000 mg ) in adults ( 18 years or age) suffering from postherpetic neuralgia. Principle Investigator 2006-2007 Medgenex, Inc A double-blind, randomized study of the efficacy of modafinil for the management of opioid-induced sedation Principle Investigator Intramural Grants and Contracts 1978-1981 University of Utah Research Committee A process study of clinical pharmacist activity in a university teaching hospital, $2,035, Principal Investigator. 1978-1981 Department of Health, Education and Welfare, Biomedical Research Support Grant Clinical Pharmacist Activity Outcome Study, Grant No. 507-RR-05738-07, $5,372, Principal Investigator. 1991-1992 University of Utah Research Committee Software development and implementation of a data system for advanced cancer pain and its management, $4,940, Principal Investigator. 2007-2008 University of Utah Interdisciplinary Seed Grant Drug Theory, Policy and Practice: An Interdisciplinary analysis $8,000, Principle Investigator
- Page 1 and 2: Arthur G. Lipman Page 1 CURRICULUM
- Page 3 and 4: Arthur G. Lipman Page 3 PUBLICATION
- Page 5 and 6: Arthur G. Lipman Page 5 Chapters an
- Page 7 and 8: Arthur G. Lipman Page 7 Articles in
- Page 9 and 10: Arthur G. Lipman Page 9 Abstracts 1
- Page 11 and 12: Arthur G. Lipman Page 11 Editorials
- Page 13 and 14: Arthur G. Lipman Page 13 Editorials
- Page 15 and 16: Arthur G. Lipman Page 15 Editorials
- Page 17 and 18: Arthur G. Lipman Page 17 Drug Thera
- Page 19 and 20: Arthur G. Lipman Page 19 Drug Thera
- Page 21 and 22: Arthur G. Lipman Page 21 Book and M
- Page 23: Arthur G. Lipman Page 23 GRANTS AND
- Page 27 and 28: Arthur G. Lipman Page 27 EDITORIAL
- Page 29 and 30: Arthur G. Lipman Page 29 Membership
- Page 31 and 32: Arthur G. Lipman Page 31 University
- Page 33 and 34: Arthur G. Lipman Page 33 CONTRIBUTE
- Page 35 and 36: Arthur G. Lipman Page 35 INVITED PR
- Page 37 and 38: Arthur G. Lipman Page 37 INVITED PR
- Page 39 and 40: Arthur G. Lipman Page 39 INVITED PR
- Page 41 and 42: Arthur G. Lipman Page 41 INVITED PR
- Page 43 and 44: Arthur G. Lipman Page 43 I*NVITED P
- Page 45 and 46: Arthur G. Lipman Page 45 INVITED PR
- Page 47 and 48: Arthur G. Lipman Page 47 INVITED PR
- Page 49 and 50: Arthur G. Lipman Page 49 INVITED PR
- Page 51 and 52: Arthur G. Lipman Page 51 INVITED PR
- Page 53 and 54: Arthur G. Lipman Page 53 INVITED PR
- Page 55 and 56: Arthur G. Lipman Page 55 INVITED PR
- Page 57 and 58: Arthur G. Lipman Page 57 ] INVITED
- Page 59: Arthur G. Lipman Page 59 COMMUNITY
<strong>Arthur</strong> G. <strong>Lipman</strong><br />
Page 24<br />
Extramural Grants and Contracts - continued<br />
1990-1991 Hoechst-Roussell <strong>Pharm</strong>aceuticals, Inc.<br />
Development of a data system <strong>for</strong> advanced cancer pain and its management, $5,000, Principal investigator.<br />
1994 Syntex Laboratories<br />
Development of a continuing education program on pathophysiology and management of pain, $51,425<br />
Principal investigator.<br />
1996-1997 Vista <strong>Hospice</strong> Care Foundation<br />
Postdoctoral training program in pain and palliative care., $58,000 per year,<br />
Principal investigator.<br />
1997-1099 VistaCare Foundation, Scottsdale Arizona<br />
Support <strong>for</strong> a Post Doctoral Fellowship in Pain and Palliative Care <strong>Pharm</strong>acy Research, $66,000 per year,<br />
Principal Investigator.<br />
1998-1999 Alza Corporation<br />
Evaluation of E-TRANS (iontophoretic delivery) fentanyl <strong>for</strong> the treatment of breakthrough pain in conjunction<br />
with chronic pain, $22,000 Principle Investigator<br />
1998-1999 Durect Corporation<br />
Study of subcutaneous sufentanyl in chronic pain management, $56,000, Principle Investigator<br />
1998-1999 Robert Wood Johnson Foundation<br />
Utah partnership <strong>for</strong> improving care at the end of life planning grant, $75,000, Steering Committee member.<br />
1999-2000 Purdue <strong>Pharm</strong>a<br />
Physician Perceptions of the Role of Opioids in Chronic Nonmalignant Pain, Principle Investigator, $ 10,000<br />
1999-2001 American Pain Society<br />
Development of clinical practice guidelines <strong>for</strong> pain management in arthritis, Co-Chair-Co Principle<br />
Investigator, $25,000<br />
2000-2002 Robert Wood Johnson Foundation<br />
Utah partnership <strong>for</strong> improving care at the end of life implementation grant, $375,000, Steering Committee<br />
member<br />
2001 <strong>Pharm</strong>acia Corp,<br />
Systematic Review Of Adverse Effects of Perioperative, Principle Investigator, $10,000<br />
2001 <strong>Pharm</strong>acia Corp.<br />
Costs of adverse reactions to opioids in post surgical patients, Co-Investigator, $125,000<br />
2001 American Pain Society Evidence Based Guidelines Program<br />
Systematic Review of the Effect of Pain and Opioids on Immune Response. Principle Investigator, $15,000<br />
2001-2002 Janssen <strong>Pharm</strong>aceutica<br />
Outcomes study of controlled release opioids in low back pain , Co-investigator, 55,000.<br />
2001-2002 Endo Pharamceuticals<br />
Dermal Lidocaine <strong>for</strong> Myofascial Pain, Principle Investigator, $26,000<br />
2002-2007 NIH/NCI 2R01CA07424906A1<br />
Pain and the Defense Response<br />
To study the effects of pharmacological manipulated noradrenergic arousal on the defense response.<br />
Sub investigator<br />
2003-2004 Progenics <strong>Pharm</strong>aceuticals MNTX 301<br />
A double-blind placebo-controlled study of methylnaltrexone (MNTX) <strong>for</strong> the relief of symptomatic<br />
constipation due to chronic opioid therapy in patients with advanced medical illness.<br />
Principal Investigator<br />
2003-2004 Glaxo Smith Kline SB 767905-001<br />
A randomized, double-blind, placebo-controlled, multicenter phase 3B study to evaluate the efficacy<br />
and safety of multiple alvimopan dosage regimens <strong>for</strong> the treatment of opioid-induced bowel<br />
dysfunction in subjects with chronic pain of non-malignant origin.<br />
Co-investigator<br />
continued
Change language